Despite the fact that the initial attempts to target EPHA2 in order to enhance the specificity of adenoviral vectors were not fruitful [46], the development of EPHA2-specific antibody agonists and ephrinA1 antagonists suppressed tumor growth and metastatic disease, inhibiting angiogenesis in mice with orthotopical transplantation of MiaPaCa2 cells [47]. This evidence concerns the gene EPHA2 and metastatic neoplasm.